RLMD Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY.

$16.93
As of 12/03/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  USA
Country of incorporation:  USA
IPO date:  06/20/2014
Outstanding shares:  17,530,830
Average volume:  90,581
Market cap:   $312,925,316
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    75955J402
ISIN:        US75955J4022
Sedol:      BK71LV3
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   4.08
PS ratio:   0.00
Return on equity:   -154.27%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy